retatrutide results women Results: How Much Weight Can You Lose & How Quick? Retatrutide is changing the conversation

New from the Diagnosing Health Care Podcast: The recent 2024 elections resulted in a new Trump administration and a Republican-controlled House and Senate

& Xia, X

Tirzepatide, a dual glucagon-like peptide-1 (GIP) and GLP-1RAs, administered once weekly at a 15 mg dose, resulted in an average weight loss of 20.9% over 72 weeks (Jastreboff et al., 2022), driven by its synergistic effects on appetite regulation, energy intake reduction, and fat mass decrease (Heise et al., 2023)

Over time, BPC-157 has become the subject of extensive preclinical investigation , particularly in laboratory and animal-based experimental models focused on tissue integrity, structural recovery mechanisms, and gastrointestinal physiology

Because tirzepatide delays gastric emptying, clinicians should also know about its use before general anaesthesia or deep sedation

The peptides under review at the July 2026 FDA meeting including BPC-157, TB-500, CJC-1295, and others are not FDA-approved drugs and will not become FDA-approved drugs as a result of this meeting